Doctors study hidden social struggles of liver patients
NCT ID NCT07191886
First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times
Summary
This study looks at the social and economic challenges faced by people with chronic liver disease, like trouble paying for food or housing. Researchers will survey 400 patients and their doctors at Indiana University Health to find out what needs are most common and how patients want their care team to help. The goal is to create a better way to address these issues in routine liver care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a standard way for doctors to ask about and address social needs in liver disease care.
- What could go wrong
- This is an observational study, not testing a treatment. It may not change care if patients or providers are unwilling to participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2024
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults with chronic liver disease receiving outpatient care in hepatology clinics at Indiana University Health University Hospital and providers delivering care during the study visits.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient Inclusion criteria * Age 18 or greater * English speaking * Ability to give consent (West Haven stage 0-1 if history of hepatic encephalopathy) Provider Inclusion Criteria • Participated in patient care during inclusion visit Exclusion Criteria: * Patient Exclusion criteria * History of liver transplant * Individuals not willing to participate in the survey * Patients with severe cognitive impairment Provider Exclusion Criteria • Unable to complete survey within 7 days of the inclusion visit
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Indiana University School of Medicine
RECRUITINGIndianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New blood panel aims to catch liver cancer before it spreads
- Spleen surgery may reshape cholesterol in cirrhosis
- Spleen surgery and kidney health: a hidden connection in cirrhosis?
- Could a 5-Day drug course make surgery safer for liver patients with low platelets?
- Stick-On ultrasound patch could spot liver damage without a specialist
- Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients